AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Adults with Ulcerative Colitis
Shots:
- The approval was based on the 3 P-III studies i.e., (U-ACHIEVE), (U-ACCOMPLISH) & (U-ACHIEVE) evaluating upadacitinib (45mg, qd as induction therapy) & 15/30mg, qd as maintenance therapy vs PBO for active UC
- In an induction & maintenance trial, 26%/33% of patients treated with Rinvoq (45mg) achieved clinical remission @8wk. vs 5% & 4% in PBO; 42% & 52% vs 12% with Rinvoq (15/30mg) & corticosteroid-free remission (57% & 68% vs 22%) for ≥90 days @52wk.
- In (U-ACHIEVE) & (U-ACCOMPLISH) trials, 73% & 74% achieved clinical response in 45mg dose @8wk. vs 27% & 25%; clinical response per partial Adapted Mayo Score @2wk. (60% & 63%) vs (27% vs 26%), mucosal healing (36% & 44% vs 7% & 8%) @8wk.; 49% & 62% vs 14% in maintenance study @45wk.
Ref: AbbVie | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.